Key result
In patients with non-obstructive coronary artery disease, detectable high-sensitivity cardiac troponin I was independently associated with an increased risk of cardiovascular death and nonfatal myocardial infarction (adjusted HR 8.927).
Why the study?
Mild elevation of serum cardiac troponin reflects myocardial injury and is associated with cardiovascular events, but its mechanism and prognostic impact in non-obstructive CAD remained to be investigated.
Does detectable hs-cTnI predict adverse events in patients with non-obstructive CAD?
Cohort (n=474)
No
Does detectable hs-cTnI predict adverse events in patients with non-obstructive CAD?
Hazard Ratio: 8.927 (95% CI 1.341–149.48)
p-value: p=0.028
In patients with non-obstructive CAD, low-level hs-cTnI elevation predicts adverse events independent of myocardial ischemia due to microvascular dysfunction.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2022) conducted a cohort in Non-obstructive coronary artery disease (n=474). Detectable high-sensitivity cardiac troponin I (≥0.001 ng/ml) vs. Undetectable hs-cTnI (<0.001 ng/ml) was evaluated on Composite of cardiovascular death and nonfatal myocardial infarction (HR 8.927, 95% CI 1.341-149.48, p=0.028). In patients with non-obstructive coronary artery disease, detectable high-sensitivity cardiac troponin I was independently associated with an increased risk of cardiovascular death and nonfatal myocardial infarction (adjusted HR 8.927).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: